Last updated: 2026-09-09 05:11:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
NewAmsterdam Pharma Company N.V. (NAMS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $25.66, with a market capitalization of $3.04B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.27 to $42.21. This page covers its latest market performance, valuation, price trends and company information.
$3.04B | |
$24.02 | |
$42.21 | |
$5.63 | |
$25.40 | |
3.57M | |
1.07M | |
-- | |
$42.21 | |
$22.27 | |
-- | |
-- |
NewAmsterdam Pharma Company N.V. (NAMS) last closed at $25.40 as of 2026-09-08 23:31:00, unchanged from the previous close of $25.40.
During the latest regular trading session, NAMS traded between $5.63 and $42.21, with a volume of 3.57M shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, NewAmsterdam Pharma Company N.V. (NAMS) moved from $26.79 to $25.66, representing a decline of 4.22% ($1.13).
The stock traded between $22.27 and $27.60 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 884.90 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 17.0%
NAMS is currently trading at $25.66, placing it 17.0% of the way from its 52-week low of $22.27 to its 52-week high of $42.21. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 100 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NewAmsterdam Pharma Company N.V. (NAMS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.